Quick Answer
ADMA BIOLOGICS, INC. reported Cash and Equivalents of $87.63 million for fiscal year 2025.
ADMA BIOLOGICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $87.63M | -15.0% |
| 2024 | $103.15M | +100.9% |
| 2023 | $51.35M | -40.6% |
| 2022 | $86.52M | +69.4% |
| 2021 | $51.09M | -8.6% |
| 2020 | $55.92M | +109.0% |
| 2019 | $26.75M | -0.0% |
| 2018 | $26.75M | -37.9% |
| 2017 | $43.11M | +334.8% |
| 2016 | $9.91M | -5.0% |
| 2015 | $10.44M | -39.3% |
| 2014 | $17.20M | -34.2% |
| 2013 | $26.15M | +108.6% |
| 2012 | $12.54M | +14182.2% |
| 2011 | $87.8K | -61.7% |
| 2010 | $229.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $61.38M | -29.2% | -32.0% |
| June 30, 2025 | $90.28M | +2.3% | +26.1% |
| March 31, 2025 | $71.62M | +58.0% | -30.6% |
| December 31, 2024 | $103.15M | +100.9% | +19.0% |
| September 30, 2024 | $86.71M | +16.9% | -1.7% |
| June 30, 2024 | $88.24M | +41.2% | +94.7% |
| March 31, 2024 | $45.33M | -34.5% | -11.7% |
| December 31, 2023 | $51.35M | -40.6% | -30.8% |
- ADMA BIOLOGICS, INC. showed a decrease of -15.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, ADMA BIOLOGICS, INC.’s cash and equivalents has grown by 38171.2% (from $229.0 thousand to $87.63 million).
- The most recent figure is from ADMA BIOLOGICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: